Tissue-targeted medicines, designed in vivo
Manifold Bio has built the first high-throughput in vivo (HTV) discovery engine—combining massively multiplexed in vivo screening and AI-powered design to create targeted biologics.
In vitro is not in vivo
Even the best AI models can only optimize for the context they are trained on. In vitro assays fail to recapitulate the complexity of living systems, missing key properties like PK and biodistribution.
Design, build, track, learn. All in-vivo.
We combine cutting-edge AI-guided protein design with the ability to directly test these designs in living systems.
Our engine sculpts pharmacokinetics, biodistribution, and other key properties of biologics directly in living systems, solving previously intractable challenges for tissue-specific delivery.
We have invented molecular tracking technologies that massively expand the scale of in vivo measurement of biologics. We don’t simulate biology, we have the wetware to measure it.
Novel wetware to enable HTV tracking
AI-guided protein design
Towards an in vivo world model
In the limit, we’re building a predictive model of living systems — one that integrates high-throughput in vivo data to map how biomolecules behave in the complexity of the body. This model empowers rational design of therapeutics by closing the loop between molecule, in vivo biology, and therapeutic outcome.
Targeted medicines spanning tissues and modalities.
Expanding the potential of tissue-targeted medicines across modalities and therapeutic areas through internal development and strategic partnerships.
mShuttle Portfolio
Growing a modular library of shuttles engineered and optimized in vivo to deliver payloads precisely, across any tissue, with high specificity and exposure.
In vivo shuttle profiles characterized with mCodes
Manifold shuttle portfolio with diverse profiles
Optimal shuttle therapeutics
Pipeline of potent biologics through tissue-specificity
Starting with brain-specific delivery, Manifold’s engine is enabling potent, tolerable new drug candidates, including programs targeting neurodegenerative disease.
CNS-targeted
Abeta
High CNS levels of full-effector function mAb safety engages brain immune system to clear plaques and avoids peripheral toxicities
Alzheimer’s
tau
Sustained CNS levels of mAb to block neuron-to-neuron spread of pathological tau
Alzheimer’s + rare disease
tau
Knockdown of intracellular tau by targeting oligos directly to neurons after peripheral dosing
Alzheimer’s + rare disease
aSyn
Sustained CNS levels of mAb to block neuron-to-neuron spread of pathological alpha-synuclein
Parkinson’s + rare disease
aSyn
Knockdown of intracellular synuclein by targeting oligos directly to neurons after peripheral dosing
.png)
Alzheimer’s + rare disease
Peripheral-targeted
Undisclosed
Specific target engagement in adipose tissue while detangling liver/kidney
Cardiometabolic disease
Co-design precision biologics with our in vivo, ML-guided engine
Board
Steve Holtzman
Executive Chairman
Gleb Kuznetsov, Phd
Co-Founder & CEO
Pierce Ogden, PhD
Co-Founder & CTO
Jory Bell
Playground Global
Jeff Huber
Triatomic Capital
Steve Kafka
Section 32
Contact us